Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model

Immunobiology

Volumn 220, Issue 12, 2015, Pages 1293-1304

  Bazzi, Samer ^a,b   Modjtahedi, Helmout ^a   Mudan, Satvinder ^c,d   Akle, Charles ^e   Bahr, Georges M ^b  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BALAMAND   (Lebanon)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e London Clinic Cancer Centre   (United Kingdom)

Author keywords

CD antigens; Human leukocytes; Immunomodulation; Mycobacteria

Indexed keywords

CELL SURFACE RECEPTOR; CHEMOKINE; COMPLEMENT RECEPTOR; CYTOKINE; FC RECEPTOR; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MYCOBACTERIUM; MYCOBACTERIUM OBUENSE; MYCOBACTERIUM VACCAE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION; GENETICS; HEAT; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKOCYTE; METABOLISM; MONONUCLEAR CELL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, CD11C; CHEMOKINES; CYTOKINES; GENE EXPRESSION; HLA-DR ANTIGENS; HOT TEMPERATURE; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; MYCOBACTERIUM; NEUTROPHILS; TOLL-LIKE RECEPTORS;

EID: 84942830712     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.07.015     Document Type: Article

References (77)

1. Abbot N.C., Beck J.S., Feval F., Weiss F., Mobayen M.H., Ghazi-Saidi K., et al. Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial. Eur. J. Vasc. Endovasc. Surg. 2002, 24:202-208.
2. Adams V.C., Hunt J.R., Martinelli R., Palmer R., Rook G.A., Brunet L.R. Mycobacterium vaccae induces a population of pulmonary CD11c+ cells with regulatory potential in allergic mice. Eur. J. Immunol. 2004, 34:631-638.
3. Antas P.R., Cardoso F.L., Oliveira E.B., Gomes P.K., Cunha K.S., Sarno E.N., et al. Whole blood assay to access T cell-immune responses to Mycobacterium tuberculosis antigens in healthy Brazilian individuals. Mem. Inst. Oswaldo Cruz 2004, 99:53-55.
4. Arkwright P.D., David T.J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J. Allergy Clin. Immunol. 2001, 107:531-534.
5. Asea A., Kraeft S.K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 2000, 6:435-442.
6. Bahr G.M., De La Tribonniere X., Darcissac E., Ajana F., Bocket L., Sissoko D., et al. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. J. Antimicrob. Chemother. 2003, 51:1377-1388.
7. Bahr G.M., Stanford J.L., Rook G.A., Rees R.J., Frayha G.J., Abdelnoor A.M. Skin sensitization to mycobacteria amongst school children prior to a study of BCG vaccination in North Lebanon. Tubercle 1986, 67:197-203.
8. Baran J., Baj-Krzyworzeka M., Weglarczyk K., Ruggiero I., Zembala M. Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae. Cancer Immunol. Immunother. 2004, 53:1127-1134.
9. Barclay A.N., Brown M.H., Law S.K.A., McKnight A.I., Tomhnson M.G., van der Merwe P. The Leucocyte Antigen Facts Book 1997, Academic Press, San Diego. 2nd ed.
10. Behr M.A., Divangahi M. Freund's adjuvant, NOD2 and mycobacteria. Curr. Opin. Microbiol. 2015, 23:126-132.
11. Black G.F., Dockrell H.M., Crampin A.C., Floyd S., Weir R.E., Bliss L., et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J. Infect. Dis. 2001, 184:322-329.
12. Camporota L., Corkhill A., Long H., Lordan J., Stanciu L., Tuckwell N., et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur. Respir. J. 2003, 21:287-293.
13. Cananzi F.C., Mudan S., Dunne M., Belonwu N., Dalgleish A.G. Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Hum. Vaccin Immunother. 2013, 9:2427-2433.
14. Capece D., Verzella D., Fischietti M., Zazzeroni F., Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J. Biomed. Biotechnol. 2012, 926321.
15. Dalgleish, A.G. and The IMAGE I Trial Investigators, 2015. A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer, Anonymous 2015, pp. 336.
16. Damsgaard C.T., Lauritzen L., Calder P.C., Kjaer T.M., Frokiaer H. Whole-blood culture is a valid low-cost method to measure monocytic cytokines - a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes. J. Immunol. Methods 2009, 340:95-101.
17. Darcissac E.C., Bahr G.M., Parant M.A., Chedid L.A., Riveau G.J. Selective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides. Cell. Immunol. 1996, 169:294-301.
18. Darcissac E.C., Bahr G.M., Pouillart P.R., Riveau G.J., Parant M.A. Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue. Cytokine 1996, 8:658-666.
19. Deenadayalan A., Maddineni P., Raja A. Comparison of whole blood and PBMC assays for T-cell functional analysis. BMC Res. Notes 2013, 6. 120-0500-6-120.
20. Dlugovitzky D., Fiorenza G., Farroni M., Bogue C., Stanford C., Stanford J. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir. Med. 2006, 100:1079-1087.
21. Driessens G., Kline J., Gajewski T.F. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 2009, 229:126-144.
22. Duffy D., Rouilly V., Libri V., Hasan M., Beitz B., David M., et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 2014, 40:436-450.
23. Eaton J.D., Perry M.J., Nicholson S., Guckian M., Russell N., Whelan M., et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int. 2002, 89:19-26.
24. Elia A., Lincoln L., Brunet L., Hagemann T. Treatment with IMM-101 induces protective CD8+ T cell responses in clinically relevant models of pancreatic cancer. J. ImmunoTher. Cancer 2013, 1:P215.
25. Flo T.H., Halaas O., Torp S., Ryan L., Lien E., Dybdahl B., et al. Differential expression of Toll-like receptor 2 in human cells. J. Leukoc. Biol. 2001, 69:474-481.
26. Fowler D.W., Copier J., Wilson N., Dalgleish A.G., Bodman-Smith M.D. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol. Immunother. 2012, 61:535-547.
27. Gaglia J.L., Greenfield E.A., Mattoo A., Sharpe A.H., Freeman G.J., Kuchroo V.K. Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J. Immunol. 2000, 165:6091-6098.
28. Gramaglia I., Cooper D., Miner K.T., Kwon B.S., Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol. 2000, 30:392-402.
29. Hermann C., von Aulock S., Graf K., Hartung T. A model of human whole blood lymphokine release for in vitro and ex vivo use. J. Immunol. Methods 2003, 275:69-79.
30. Hogarth P.M., Pietersz G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discovery 2012, 11:311-331.
31. Ivetic A. Signals regulating l-selectin-dependent leucocyte adhesion and transmigration. Int. J. Biochem. Cell Biol. 2013, 45:550-555.
32. Janke M., Poth J., Wimmenauer V., Giese T., Coch C., Barchet W., et al. Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. J. Allergy Clin. Immunol. 2009, 123:1026-1033.
33. Johnson J.L., Kamya R.M., Okwera A., Loughlin A.M., Nyole S., Hom D.L., et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 2000, 181:1304-1312.
34. Kartalija M., Ovrutsky A.R., Bryan C.L., Pott G.B., Fantuzzi G., Thomas J., et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am. J. Respir. Crit. Care Med. 2013, 187:197-205.
35. Kassa D., Ran L., Geberemeskel W., Tebeje M., Alemu A., Selase A., et al. Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis. Clin. Vaccine Immunol. 2012, 19:1907-1915.
36. Kato M., Neil T.K., Fearnley D.B., McLellan A.D., Vuckovic S., Hart D.N. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int. Immunol. 2000, 12:1511-1519.
37. Kawai K., Miyazaki J., Joraku A., Nishiyama H., Akaza H. Bacillus calmette-guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013, 104:22-27.
38. Killick K.E., Ni Cheallaigh C., O'Farrelly C., Hokamp K., MacHugh D.E., Harris J. Receptor-mediated recognition of mycobacterial pathogens. Cell. Microbiol. 2013, 15:1484-1495.
39. Kleinnijenhuis J., Oosting M., Joosten L.A., Netea M.G., Van Crevel R. 2011. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011, 405310.
40. Lagrelius M., Jones P., Franck K., Gaines H. Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine 2006, 33:156-165.
41. Le Bert N., Chain B.M., Rook G., Noursadeghi M. DC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathway. PLoS One 2011, 6:e18346.
42. Lehrer A., Bressanelli A., Wachsmann V., Bottasso O., Bay M.L., Singh M., et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol. Med. Microbiol. 1998, 21:71-77.
43. Lopez R.D., Waller E.K., Lu P.H., Negrin R.S. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol. Immunother. 2001, 49:629-640.
44. Martinelli R., Adams V.C., Rook G.A.W., Brunet L.R. Effects of Mycobacterium vaccae on toll-like receptor expression. J. Allergy Clin. Immunol. 2004, 113:S187.
45. Moreira J., Aragao-Filho W.C., Barillas S.G., Barbosa S.M., Pedroza L.A., Condino-Neto A. Human leucocytes response to viable, extended freeze-drying or heat-killed Mycobacterium bovis bacillus Calmette-Guerin. Scand. J. Immunol. 2012, 75:96-101.
46. Myers N.D., Chantratita N., Berrington W.R., Chierakul W., Limmathurotsakul D., Wuthiekanun V., et al. The role of NOD2 in murine and human melioidosis. J. Immunol. 2014, 192:300-307.
47. Nijhuis M.M., Pasterkamp G., Sluis N.I., de Kleijn D.P., Laman J.D., Ulfman L.H. Peptidoglycan increases firm adhesion of monocytes under flow conditions and primes monocyte chemotaxis. J. Vasc. Res. 2007, 44:214-222.
48. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
49. Noorman F., Braat E.A., Barrett-Bergshoeff M., Barbe E., van Leeuwen A., Lindeman J., et al. Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages. J. Leukoc. Biol. 1997, 61:63-72.
50. O'Brien M.E., Anderson H., Kaukel E., O'Byrne K., Pawlicki M., Von Pawel J., et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann. Oncol. 2004, 15:906-914.
51. Oftung F., Borka E., Kvalheim G., Mustafa A.S. Mycobacterial crossreactivity of M. tuberculosis reactive T cell clones from naturally converted PPD positive healthy subjects. FEMS Immunol. Med. Microbiol. 1998, 20:231-238.
52. Patel P.M., Sim S., O'Donnell D.O., Protheroe A., Beirne D., Stanley A., et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur. J. Cancer 2008, 44:216-223.
53. Popa C., Barrera P., Joosten L.A., van Riel P.L., Kullberg B.J., van der Meer J.W., et al. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur. Cytokine Network 2009, 20:88-93.
54. Reichenbach J., Schubert R., Feinberg J., Beck O., Rosewich M., Rose M.A., et al. Impaired interferon-gamma production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia. Clin. Exp. Immunol. 2006, 146:381-389.
55. Romano M., Huygen K. An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time. Expert Opin. Biol. Ther. 2012, 12:1601-1610.
56. Rook G.A., Adams V., Hunt J., Palmer R., Martinelli R., Brunet L.R. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin. Immunopathol. 2004, 25:237-255.
57. Santucci M.B., Amicosante M., Cicconi R., Montesano C., Casarini M., Giosue S., et al. Mycobacterium tuberculosis-induced apoptosis in monocytes/macrophages: early membrane modifications and intracellular mycobacterial viability. J. Infect. Dis. 2000, 181:1506-1509.
58. Schleiffenbaum B., Spertini O., Tedder T.F. Soluble l-selectin is present in human plasma at high levels and retains functional activity. J. Cell Biol. 1992, 119:229-238.
59. Sieling P.A., Torrelles J.B., Stenger S., Chung W., Burdick A.E., Rea T.H., et al. The human CD1-restricted T cell repertoire is limited to cross-reactive antigens: implications for host responses against immunologically related pathogens. J. Immunol. 2005, 174:2637-2644.
60. Silva D., Ponte C.G., Hacker M.A., Antas P.R. A whole blood assay as a simple, broad assessment of cytokines and chemokines to evaluate human immune responses to Mycobacterium tuberculosis antigens. Acta Trop. 2013, 127:75-81.
61. Skinner M.A., Yuan S., Prestidge R., Chuk D., Watson J.D., Tan P.L. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect. Immun. 1997, 65:4525-4530.
62. Smalley D.M., Ley K. l-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell. Mol. Med. 2005, 9:255-266.
63. Stanford J., Stanford C., Stansby G., Bottasso O., Bahr G., Grange J. The common mycobacterial antigens and their importance in the treatment of disease. Curr. Pharm. Des. 2009, 15:1248-1260.
64. Stanford J.L., Stanford C.A., O'Brien M.E., Grange J.M. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer 2008, 44:224-227.
65. Stebbing J., Dalgleish A., Gifford-Moore A., Martin A., Gleeson C., Wilson G., et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann. Oncol. 2012, 23:1314-1319.
66. Thibodeau J., Bourgeois-Daigneault M.C., Lapointe R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 2012, 1:908-916.
67. Truoc L.V., Ly H.M., Thuy N.K., Trach D.D., Stanford C.A., Stanford J.L. Vaccination against leprosy at Ben San Leprosy Centre, Ho Chi Minh City, Vietnam. Vaccine 2001, 19:3451-3458.
68. Tsuyuguchi I., Kawasumi H., Takashima T., Tsuyuguchi T., Kishimoto S. Mycobacterium avium-Mycobacterium intracellular complex-induced suppression of T-cell proliferation in vitro by regulation of monocyte accessory cell activity. Infect. Immun. 1990, 58:1369-1378.
69. van Egmond M., Bakema J.E. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin. Cancer Biol. 2013, 23:190-199.
70. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in bacille calmette-guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685.
71. Wang Y., Kelly C.G., Singh M., McGowan E.G., Carrara A.S., Bergmeier L.A., et al. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J. Immunol. 2002, 169:2422-2429.
72. Weir R.E., Fine P.E., Nazareth B., Floyd S., Black G.F., King E., et al. Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria. Clin. Exp. Immunol. 2003, 134:285-294.
73. Wingren A.G., Parra E., Varga M., Kalland T., Sjogren H.O., Hedlund G., et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol 1995, 15:235-253.
74. Wollenberg A., Mommaas M., Oppel T., Schottdorf E.M., Gunther S., Moderer M. Expression and function of the mannose receptor CD206 on epidermal dendritic cells in inflammatory skin diseases. J. Invest. Dermatol. 2002, 118:327-334.
75. Yang X.Y., Chen Q.F., Li Y.P., Wu S.M. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011, 6:e23826.
76. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.
77. Zuany-Amorim C., Sawicka E., Manlius C., Le Moine A., Brunet L.R., Kemeny D.M., et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 2002, 8:625-629.